Want to see AU:CTE full AI Analyst Report?
Top Page
Cryosite Limited
(Sydney:CTE)
Select Model
Select Model
Rating:61Neutral
Price Target:
AU$1.50
▲(20.00% Upside)
Action:Reiterated
Date:08/20/26
The score is primarily held back by financial risk factors—meaningfully higher leverage and a sharp swing to deeply negative free cash flow in 2026—despite solid revenue growth and strong operating profitability. Technicals are moderately supportive (price above major moving averages), while valuation is somewhat demanding given the ~27 P/E and no dividend yield data.
Positive Factors
Revenue Growth
The sustained increase in revenue indicates expanding demand for Cryosite’s temperature-controlled life-sciences logistics and storage services, supporting a larger operating base and providing a durable foundation for future earnings growth.
Negative Factors
Higher Financial Leverage
The sharp increase in debt reduces financial flexibility for a relatively small company and raises sensitivity to operating setbacks. Higher leverage may constrain investment choices and increase dependence on sustained earnings and cash generation.
Read all positive and negative factors
Positive Factors
Negative Factors
Revenue Growth
The sustained increase in revenue indicates expanding demand for Cryosite’s temperature-controlled life-sciences logistics and storage services, supporting a larger operating base and providing a durable foundation for future earnings growth.
Read all positive factors
Cryosite Limited (CTE) vs. iShares MSCI Australia ETF (EWA)
Market Cap
AU$61.01M
Dividend YieldN/A
Average Volume (3M)1.97K
Price to Earnings (P/E)27.3
Beta (1Y)-0.18
Revenue Growth18.31%
EPS Growth18.65%
CountryAU
Employees27
SectorHealthcare
Sector Strength45
IndustryMedical - Diagnostics & Research
Share Statistics
EPS (TTM)0.05
Shares Outstanding48,809,563
10 Day Avg. Volume3,337
30 Day Avg. Volume1,969
Financial Highlights & Ratios
PEG Ratio1.46
Price to Book (P/B)12.58
Price to Sales (P/S)3.65
P/FCF Ratio-7.50
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Cryosite Limited Business Overview & Revenue Model
Company Description
Cryosite Limited, founded in 1999 and headquartered in South Granville, Australia, specializes in providing outsourced logistics and storage solutions to the life sciences industry within Australia. The company operates through two distinct divisi...
How the Company Makes Money
null...
Cryosite Limited Financial Statement Overview
Summary
Income Statement
78
Positive
Balance Sheet
58
Neutral
Cash Flow
42
Neutral
| Breakdown | Jun 2026 | Jun 2025 | Jun 2024 | Jun 2023 | Jun 2022 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 16.70M | 14.12M | 12.61M | 11.94M | 11.76M |
| Gross Profit | 9.51M | 8.89M | 7.99M | 6.48M | 6.27M |
| EBITDA | 4.07M | 3.41M | 3.04M | 2.30M | 2.40M |
| Net Income | 2.23M | 1.88M | 1.84M | 1.41M | 1.36M |
Balance Sheet | |||||
| Total Assets | 25.97M | 19.46M | 19.71M | 22.65M | 21.50M |
| Cash, Cash Equivalents and Short-Term Investments | 2.24M | 5.06M | 4.70M | 5.73M | 5.34M |
| Total Debt | 7.72M | 2.27M | 2.44M | 2.61M | 849.76K |
| Total Liabilities | 21.12M | 17.07M | 18.26M | 19.86M | 19.64M |
| Stockholders Equity | 4.85M | 2.39M | 1.45M | 2.78M | 1.86M |
Cash Flow | |||||
| Free Cash Flow | -8.14M | 1.48M | 2.44M | 1.19M | 1.63M |
| Operating Cash Flow | 2.73M | 2.06M | 2.90M | 1.49M | 2.49M |
| Investing Cash Flow | -10.87M | -420.00K | 727.00K | -1.33M | -863.19K |
| Financing Cash Flow | 5.33M | -1.29M | -3.50M | -768.00K | -148.99K |
Cryosite Limited Technical Analysis
Positive
1.25
Price Trends
1.22
Positive
1.14
Positive
1.13
Positive
Market Momentum
0.01
Negative
69.73
Neutral
>-0.01
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AU:CTE, the sentiment is Positive. The current price of 1.25 is above the 20-day moving average (MA) of 1.23, above the 50-day MA of 1.22, and above the 200-day MA of 1.13, indicating a bullish trend. The MACD of 0.01 indicates Negative momentum. The RSI at 69.73 is Neutral, neither overbought nor oversold. The STOCH value of >-0.01 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for AU:CTE.
Cryosite Limited Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
71 Outperform | AU$268.85M | 17.99 | 6.06% | 1.87% | -0.03% | ― | |
63 Neutral | AU$10.10B | 16.28 | 7.20% | 4.99% | 15.53% | 15.11% | |
61 Neutral | AU$61.01M | 27.29 | 52.84% | ― | 18.31% | 18.65% | |
57 Neutral | AU$308.62M | -0.75 | -114.08% | ― | 2.16% | 21.04% | |
54 Neutral | AU$553.96M | 23.79 | 15.80% | 5.42% | -0.90% | -25.09% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
47 Neutral | AU$18.17M | -1.35 | -35.10% | ― | -9.10% | 31.75% |
* Healthcare Sector Average
AU:CTE
Cryosite Limited
1.25
0.45
56.25%
AU:HLS
Healius Limited
0.43
-0.53
-55.73%
AU:GSS
Genetic Signatures Ltd.
0.08
-0.22
-72.33%
AU:SHL
Sonic Healthcare Limited
20.06
-2.92
-12.69%
AU:ACL
Australian Clinical Labs Ltd
2.86
0.28
10.94%
AU:MVF
Monash IVF Group Ltd
0.71
0.04
5.70%
Cryosite Limited Corporate Events
Cryosite doubles storage footprint and posts record FY26 results
Aug 18, 2026
Cryosite Limited has more than doubled its storage and warehousing footprint to over 4,200 square metres after acquiring a second freehold facility in Auburn and extending its principal cool room at its South Granville headquarters. The company ai...
Cryosite files 2026 corporate governance statement and ASX Appendix 4G
Aug 18, 2026
Cryosite Limited has lodged its corporate governance statement for the year ended 30 June 2026 with the ASX and published it on its website, detailing how it adheres to the ASX Corporate Governance Council’s principles and recommendations. T...
Cryosite boosts profit and doubles storage capacity as it withholds dividend
Aug 18, 2026
Cryosite Limited reported a strong improvement in trading conditions for the year ended 30 June 2026, with revenue rising 18% to $16.7 million and net profit after tax increasing 19% to $2.24 million. Key profitability metrics also advanced, as EB...
Cryosite lifts profit on higher utilisation and prepares for next growth phase
Jul 12, 2026
Cryosite reported unaudited FY2026 revenue of $16.7 million, up 18%, with EBITDA rising 27% to $4.3 million and margins expanding as utilisation of its Ferndell Street headquarters improved. Net profit after tax increased 20% to $2.3 million, with...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.